NCT02569710View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

PHASE2CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

May 11, 2018

Study Completion Date

May 11, 2018

Conditions
Chronic Hepatitis C
Interventions
DRUG

AL-335

AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).

DRUG

Odalasvir (ODV)

ODV capsules will be administered in a dose range of 25 to 50 mg.

DRUG

Simeprevir (SMV)

SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).

Trial Locations (11)

1150

Auckland Clinical Studies, Auckland

8011

Christchurch Clinical Studies Trust, Christchurch

Unknown

CAP Research Ltd, Phoenix

Republican Clinical Hospital, Chisinau

Waikato Hospital, Hamilton

P3 Research Ltd - Hawkes Bay, Havelock North

P3 Research Ltd - Wellington, Wellington

Wellington Hospital, Wellington

King's College Hospital, Brixton

NHS Greater Glasgow and Clyde Glasgow Royal Infirmary, Glasgow

Pennine Acute Hospitals Trust, Oldham

Sponsors
All Listed Sponsors
lead

Alios Biopharma Inc.

INDUSTRY

NCT02569710 - A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir | Biotech Hunter | Biotech Hunter